vilanterol   Click here for help

GtoPdb Ligand ID: 7353

Synonyms: GW642444X
Approved drug Immunopharmacology Ligand
vilanterol is an approved drug (FDA (2013))
Compound class: Synthetic organic
Comment: Vilanterol is an ultra-long-acting β2-adrenoreceptor agonist, belonging to a group of drugs termed ultra-LABAs.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 16
Topological polar surface area 91.18
Molecular weight 485.17
XLogP 4.15
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCc1cc(ccc1O)C(CNCCCCCCOCCOCc1c(Cl)cccc1Cl)O
Isomeric SMILES OCc1cc(ccc1O)[C@H](CNCCCCCCOCCOCc1c(Cl)cccc1Cl)O
InChI InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
InChI Key DAFYYTQWSAWIGS-DEOSSOPVSA-N
No information available.
Summary of Clinical Use Click here for help
Vilanterol is contained in medications alongside a corticosteroid (eg fluticasone furoate (PubChem CID 9854489 and vilanterol marketed as Breo Ellipta®) or an anticholinergic drug (umeclidinium and vilanterol marketed as Anoro Ellipta®). Both of these medications were approved by the US FDA in 2013 to treat chronic obstructive pulmonary disease (COPD). In Europe, the EMA has approved Relvar Ellipta® (fluticasone furoate and vilanterol) for asthma and COPD. In May 2015, the US FDA expanded approval of Breo Ellipta® to include treatment of asthma.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Vilanterol is a long-acting β2-adrenoceptor agonist. Upon inhalation, the drug activates airway β2-adrenoceptors which causes vasodilation of airway smooth muscle and eases breathing. The corticosteroid component of the combination drug activates the glucocorticoid receptor (GR), helping to reduce the release of pro-inflammatory chemicals in the damaged lung, thereby futher aiding breathing.
External links Click here for help
For extended ADME data see the following:

Drugs.com